BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 18346258)

  • 1. Discoid lupus erythematosus exacerbated by contact dermatitis caused by use of squaric acid dibutylester for topical immunotherapy in a patient with alopecia areata.
    Shimaoka Y; Hatamochi A; Hamasaki Y; Suzuki H; Ikeda H; Yamazaki S
    J Dermatol; 2008 Mar; 35(3):151-3. PubMed ID: 18346258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pigmentation abnormalities in the course of topical immunotherapy of alopecia areata].
    Valsecchi R; Pansera B; Rossi A; Cainelli T
    G Ital Dermatol Venereol; 1989; 124(1-2):31-2. PubMed ID: 2527809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient leucoderma appearing in an untreated area following contact immunotherapy for alopecia areata.
    Nasca MR; Micali G; Pulvirenti N; Licastro Cicero R
    Eur J Dermatol; 1998 Mar; 8(2):125-6. PubMed ID: 9649675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalisation of hair follicle morphology in C3H/HeJ alopecia areata mice after treatment with squaric acid dibutylester.
    Gardner S; Freyschmidt-Paul P; Hoffmann R; Sundberg JP; Happle R; Lindsey NJ; Tobin DJ
    Eur J Dermatol; 2000 Aug; 10(6):443-50. PubMed ID: 10980465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical squaric acid dibutylester therapy for alopecia areata.
    Flowers FP; Slazinski L; Fenske NA; Pullara TJ
    Cutis; 1982 Dec; 30(6):733-6. PubMed ID: 6756800
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of alopecia areata with squaric acid dibutylester.
    Caserio RJ
    Arch Dermatol; 1987 Aug; 123(8):1036-41. PubMed ID: 3307636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of alopecia areata with diphencyprone].
    Suditu G; Toma A; Voiculescu M
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(4):760-2. PubMed ID: 12092234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies.
    Morita K; Nakamura M; Nagamachi M; Kishi T; Miyachi Y
    J Dermatol; 2002 Oct; 29(10):661-4. PubMed ID: 12433000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical squaric acid dibutylester therapy for alopecia areata: a double-sided patient-controlled study.
    Chua SH; Goh CL; Ang CB
    Ann Acad Med Singap; 1996 Nov; 25(6):842-7. PubMed ID: 9055014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice.
    Freyschmidt-Paul P; Sundberg JP; Happle R; McElwee KJ; Metz S; Boggess D; Hoffmann R
    J Invest Dermatol; 1999 Jul; 113(1):61-8. PubMed ID: 10417620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial.
    Dall'oglio F; Nasca MR; Musumeci ML; La Torre G; Ricciardi G; Potenza C; Micali G
    J Dermatolog Treat; 2005 Feb; 16(1):10-4. PubMed ID: 15897160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical immunotherapy of alopecia areata. A follow-up study.
    Valsecchi R; Cainelli T; Foiadelli L; Rossi A
    Acta Derm Venereol; 1986; 66(3):269-72. PubMed ID: 2426909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of topical sensitizers in the treatment of alopecia areata.
    Rokhsar CK; Shupack JL; Vafai JJ; Washenik K
    J Am Acad Dermatol; 1998 Nov; 39(5 Pt 1):751-61. PubMed ID: 9810892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical therapy of alopecia areata with squaric acid dibutylester.
    Case PC; Mitchell AJ; Swanson NA; Vanderveen EE; Ellis CN; Headington JT
    J Am Acad Dermatol; 1984 Mar; 10(3):447-50. PubMed ID: 6725657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Squaric acid dibutyl ester in the treatment of severe alopecia areata].
    Miranda A; Mato F; QuiƱones PA
    Med Cutan Ibero Lat Am; 1984; 12(3):273-8. PubMed ID: 6384701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Questions raised by skin reactions observed during squaric acid dibutyl ester contact sensitization.
    Stinco G; Patrone P
    Contact Dermatitis; 2000 Jul; 43(1):52-3. PubMed ID: 10902598
    [No Abstract]   [Full Text] [Related]  

  • 17. Diphencyprone in the treatment of alopecia areata.
    Happle R; Hausen BM; Wiesner-Menzel L
    Acta Derm Venereol; 1983; 63(1):49-52. PubMed ID: 6191489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical sequelae associated with squaric acid dibutylester topical sensitization.
    Foley S; Blattel SA; Martin AG
    Am J Contact Dermat; 1996 Jun; 7(2):104-8. PubMed ID: 8796751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Squaric acid dibutylester: indications for use and efficacy in alopecia areata.
    Pardasani AG; Turner E; McMichael AJ
    Arch Dermatol; 2001 Jul; 137(7):970-2. PubMed ID: 11453831
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of severe alopecia areata with squaric acid dibutylester in pediatric patients.
    Orecchia G; Malagoli P; Santagostino L
    Pediatr Dermatol; 1994 Mar; 11(1):65-8. PubMed ID: 8170854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.